Problem

Illuminant Surgical targets the spatial disconnect in image-guided surgery: conventional navigation displays scans on a monitor while the surgeon operates on the patient, forcing continuous mental translation between the image and the anatomy. That burden can increase cognitive load, prolong procedures, constrain throughput, and contribute to misplaced implants, vascular injuries, nerve damage, repeat procedures, and extended hospital stays. The economics are meaningful: published estimates put the average cost of a spine-surgery revision at roughly $17,650–$39,643, while the company frames preventable surgical revisions as a multibillion-dollar hospital expense.

The clearest initial use case is minimally invasive spine surgery, particularly pedicle-screw placement, decompression guidance, and alignment assessment, where millimeters can determine whether a patient has a good outcome or a serious complication. Illuminant also identifies pain-management and interventional-radiology procedures as expansion markets, together representing more than 11 million annual U.S. procedures according to the company’s market description.

Product / Service

Skylight is a projection-based surgical-navigation platform intended to give clinicians an X-ray-like view directly on the patient’s body, without headsets or a separate monitor. It combines artificial intelligence, computer vision, precision tracking, non-invasive patient registration, and dynamic projection mapping. Its SkinDots adhesive markers track and register the patient, while the LightScreen technology adapts the projected anatomy as the patient or system moves. The platform is designed to work with existing intraoperative imaging systems and surgical instruments rather than requiring a wholesale change to the operating room.

The intended benefit is a more intuitive, continuous view of anatomy and tool position at the point of intervention, potentially reducing spatial uncertainty while making image-guided procedures faster and easier to perform. Illuminant describes modules for spine, pain management, and interventional radiology and says the system is designed for rapid deployment across university hospitals, ambulatory surgery centers, and specialty clinics. These remain intended capabilities: as of August 1, 2026, Skylight had not been FDA-cleared and was not available for sale or commercial use.

Market

Illuminant competes in medical-device categories spanning image-guided surgery, surgical navigation, augmented reality, computer vision, and medical robotics. Its beachhead is spine navigation, with adjacent applications in percutaneous pain procedures, biopsy, and interventional radiology. Named alternatives include Medtronic’s StealthStation, Augmedics’ xvision platform, and nView Medical; Augmedics is a particularly close conceptual comparator because it uses augmented-reality visualization for FDA-approved open and percutaneous spine procedures.

The company has meaningful development traction but is still pre-commercial rather than an established revenue business. It launched an observational study with Mount Sinai in 2023, completed prototype and preclinical work including porcine-model studies and surgeon user studies, received approximately $2.93 million across reported SBIR awards, and raised an $8.4 million seed round in April 2026. It also opened a 12,000-square-foot Los Angeles headquarters and completed initial production-equivalent systems intended to support FDA submission. However, the company’s own current disclosure says Skylight is not approved or cleared and cannot be sold or used commercially, so public evidence supports treating it as pre-revenue or, at minimum, pre-commercial.